Cash Flow Statement

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

AstraZeneca PLC, consolidated cash flow statement

US$ in millions

12 months ended:	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012	Dec 31, 2011	Dec 31, 2010
Profit before tax	1,246)	3,267)	7,718)	12,367)	10,977)
Finance income and expense	885)	445)	430)	428)	517)
Share of after tax losses of joint ventures	6)	—)	—)	—)	—)
Depreciation, amortization and impairment	3,282)	4,583)	2,518)	2,550)	2,741)
(Increase) decrease in trade and other receivables	311)	(383)	755)	(1,108)	10)
(Increase) decrease in inventories	108)	135)	(150)	(256)	88)
Increase (decrease) in trade and other payables and provisions	2,089)	414)	(1,311)	467)	(16)
Profit on disposal of subsidiary	—)	—)	—)	(1,483)	—)
Non-cash and other movements	865)	258)	(424)	(597)	(463)
Cash generated from operations	8,792)	8,719)	9,536)	12,368)	13,854)
Interest paid	(533)	(475)	(545)	(548)	(641)
Tax paid	(1,201)	(844)	(2,043)	(3,999)	(2,533)
Dividends received	—)	—)	7)	—)	—)
Interest received	140)	114)	145)	171)	174)
Net cash inflow from operating activities	7,198)	7,514)	7,100)	7,992)	10,854)
Upfront payments on business acquisitions	(3,804)	(1,158)	(1,187)	—)	(348)
Payment of contingent consideration on business acquisitions	(657)	—)	—)	—)	—)
Purchase of property, plant and equipment	(1,012)	(742)	(672)	(839)	(791)
Disposal of property, plant and equipment	158)	69)	199)	102)	83)
Purchase of intangible assets	(1,740)	(1,316)	(3,947)	(458)	(1,390)
Disposal of intangible assets	—)	35)	—)	—)	210)
Purchase of non-current asset investments	(130)	(91)	(46)	(11)	(34)
Disposal of non-current asset investments	59)	38)	43)	—)	5)
Movement in short-term investments and fixed deposits	34)	130)	3,619)	(2,743)	(125)
Payments to joint ventures	(70)	—)	—)	—)	—)
Net cash received on disposal of subsidiary	—)	—)	—)	1,772)	—)
Payments made by subsidiaries to non-controlling interests	(10)	(10)	(20)	(16)	(10)
Payments received by subsidiaries from non-controlling interests	—)	42)	—)	—)	—)
Net cash outflow from investing activities	(7,172)	(3,003)	(2,011)	(2,193)	(2,400)
Proceeds from issue of share capital	279)	482)	429)	409)	494)
Repurchase of shares	—)	—)	(2,635)	(6,015)	(2,604)
Repayment of obligations under finance leases	(36)	(27)	(17)	—)	—)
Issue of loans	919)	—)	1,980)	—)	—)
Repayment of loans	(750)	—)	(1,750)	—)	(1,741)
Dividends paid	(3,521)	(3,461)	(3,665)	(3,764)	(3,361)
Hedge contracts relating to dividend payments	(14)	(36)	48)	3)	(114)
Payments to acquire non-controlling interest	(102)	—)	—)	—)	—)
Movement in short term borrowings	520)	(5)	687)	46)	(8)
Net cash outflow from financing activities	(2,705)	(3,047)	(4,923)	(9,321)	(7,334)
Exchange rate effects	(152)	(65)	(4)	(25)	33)
Net increase (decrease) in cash and cash equivalents in the period	(2,831)	1,399)	162)	(3,547)	1,153)
Cash and cash equivalents at the beginning of the period	8,995)	7,596)	7,434)	10,981)	9,828)
Cash and cash equivalents at the end of the period	6,164)	8,995)	7,596)	7,434)	10,981)

Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).

Download chart

Cash flow statement item	Description	The company
Net cash inflow from operating activities	Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.	AstraZeneca PLC net cash inflow from operating activities increased from 2012 to 2013 but then slightly decreased from 2013 to 2014 not reaching 2012 level.
Net cash outflow from investing activities	Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.	AstraZeneca PLC net cash outflow from investing activities decreased from 2012 to 2013 and from 2013 to 2014.
Net cash outflow from financing activities	Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.	AstraZeneca PLC net cash outflow from financing activities increased from 2012 to 2013 and from 2013 to 2014.

AstraZeneca PLC (NYSE:AZN)

Cash Flow Statement